HIMS Drops After Earnings as Margin Collapse Overshadows Strong Growth
Despite beating estimates and raising full-year outlook, HIMS stock dropped after investors focused on the bigger-than-expected loss and collapsing margins.
/ 44 items
#HIMS↓
FTC Sues Hims & Hers for Sharing Health Data with Meta and Snap
FTC, Utah and California sue Hims & Hers for sharing users’ health data with Meta and Snap despite privacy promises, plus deceptive billing.
Hims & Hers Shares Plunge After FDA Panel’s First ‘No’ on a Popular Peptide
Hims & Hers shares fell after FDA advisers approved six peptides for compounding but rejected the sleep-related peptide emideltide.
FDA Panel Votes to Ease Access to Popular Peptide BPC-157
FDA advisers voted 8-6 to let compounding pharmacies make the popular peptide BPC-157 with a prescription. Not full approval.
Hims & Hers Now Offers Affordable Generic Semaglutide in Canada
Hims & Hers offers cheaper generic semaglutide in Canada ($149/mo) with medical support for weight loss care.
Hims & Hers Q1 2026 Earnings: Big Subscriber Jump But Misses Estimates – Raises Full-Year Outlook
Hims & Hers missed earnings, lost money, but grew users and expects stronger future growth with higher revenue guidance.